The subsequent phase II, open-label, multicenter FIGHT-202 trial has explored the role of pemigatinib (13.5 mg daily in three-week cycles) in three different cohorts of pretreated patients, including CCAs that harbored FGFR2 fusions or rearrangements (n = 107), those that harbored other FGF/FGFR aberrations (n = 20), and CCA patients without FGF / FGFR aberrations (n = 18) [44]. The gene discussed is FGFR2; the disease is cholangiocarcinoma.